Haikarainen T - Search Results

1

Molecular basis of JAK kinase regulation guiding therapeutic approaches: Evaluating the JAK3 pseudokinase domain as a drug target.

Virtanen A, Kettunen V, Musta K, Räkköläinen V, Knapp S, Haikarainen T, Silvennoinen O. Virtanen A, et al. Among authors: haikarainen t. Adv Biol Regul. 2024 Dec 24:101072. doi: 10.1016/j.jbior.2024.101072. Online ahead of print. Adv Biol Regul. 2024. PMID: 39755448 Free article.

2

Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling.

Abraham BG, Haikarainen T, Vuorio J, Girych M, Virtanen AT, Kurttila A, Karathanasis C, Heilemann M, Sharma V, Vattulainen I, Silvennoinen O. Abraham BG, et al. Among authors: haikarainen t. Sci Adv. 2024 Mar 8;10(10):eadl2097. doi: 10.1126/sciadv.adl2097. Epub 2024 Mar 8. Sci Adv. 2024. PMID: 38457493 Free PMC article.

3

Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity.

Miao Y, Virtanen A, Zmajkovic J, Hilpert M, Skoda RC, Silvennoinen O, Haikarainen T. Miao Y, et al. Among authors: haikarainen t. J Med Chem. 2024 Jun 27;67(12):10012-10024. doi: 10.1021/acs.jmedchem.4c00197. Epub 2024 Jun 6. J Med Chem. 2024. PMID: 38843875 Free PMC article.

4

Author Correction: AI is a viable alternative to high throughput screening: a 318-target study.

Atomwise AIMS Program. Atomwise AIMS Program. Sci Rep. 2024 Sep 16;14(1):21579. doi: 10.1038/s41598-024-70321-w. Sci Rep. 2024. PMID: 39284864 Free PMC article. No abstract available.

5

AI is a viable alternative to high throughput screening: a 318-target study.

Atomwise AIMS Program. Atomwise AIMS Program. Sci Rep. 2024 Apr 2;14(1):7526. doi: 10.1038/s41598-024-54655-z. Sci Rep. 2024. PMID: 38565852 Free PMC article.

6

The RNA-binding protein Snd1/Tudor-SN regulates hypoxia-responsive gene expression.

Saarikettu J, Lehmusvaara S, Pesu M, Junttila I, Partanen J, Sipilä P, Poutanen M, Yang J, Haikarainen T, Silvennoinen O. Saarikettu J, et al. Among authors: haikarainen t. FASEB Bioadv. 2023 Feb 21;5(5):183-198. doi: 10.1096/fba.2022-00115. eCollection 2023 May. FASEB Bioadv. 2023. PMID: 37151849 Free PMC article.

7

Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening.

Pölläniemi A, Virtanen A, Silvennoinen O, Haikarainen T. Pölläniemi A, et al. Among authors: haikarainen t. SLAS Discov. 2023 Jun;28(4):180-187. doi: 10.1016/j.slasd.2023.05.001. Epub 2023 May 5. SLAS Discov. 2023. PMID: 37149038 Free article.

8

Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.

Virtanen A, Palmroth M, Liukkonen S, Kurttila A, Haikarainen T, Isomäki P, Silvennoinen O. Virtanen A, et al. Among authors: haikarainen t. Arthritis Rheumatol. 2023 Nov;75(11):2054-2061. doi: 10.1002/art.42547. Epub 2023 Aug 3. Arthritis Rheumatol. 2023. PMID: 37134144

9

Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain.

Virtanen AT, Haikarainen T, Sampathkumar P, Palmroth M, Liukkonen S, Liu J, Nekhotiaeva N, Hubbard SR, Silvennoinen O. Virtanen AT, et al. Among authors: haikarainen t. Pharmaceuticals (Basel). 2023 Jan 4;16(1):75. doi: 10.3390/ph16010075. Pharmaceuticals (Basel). 2023. PMID: 36678572 Free PMC article.

10

Aiming for the pocket.

Silvennoinen O, Haikarainen T, Virtanen A. Silvennoinen O, et al. Among authors: haikarainen t. Nat Chem Biol. 2022 Dec;18(12):1296-1297. doi: 10.1038/s41589-022-01120-5. Nat Chem Biol. 2022. PMID: 36097296 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

47 results

Search Page

Filters